Th e genetic basis of both sporadic and familial colorectal cancer (CRC) is among the best characterized of all human cancers. Th e genetic basis for several familial CRC syndromes (Lynch syndrome, familial adenomatous polyposis, MUTY-H-associated polyposis, juvenile polyposis, Peutz -Jaegers syndrome, and PTEN hamartomatous syndromes) has been at least partially defi ned ( 1 ) . Recently, however, it has become clear that in addition to adenomas and hamartomas, some types of serrated polyps appear to be precursors of CRCs ( 2 -5 ) . Huang et al. ( 6 ) , in a review previously published in this journal, report that 15 -20 % of all CRCs arise via the serrated pathway and it has been suggested that these lesions may have an important role in interval or missed cancers ( 7 ) and that the polyp to cancer progression may be accelerated in the serrated neoplasia pathway ( 8 ) . Serrated polyps include hyperplastic polyps, sessile serrated adenomas / polyps with or without cytologic dysplasia and traditional serrated polyps. Individuals with numerous (up to hundreds) serrated polyps of the colon have been described and the WHO (World Health Organization) has proposed clinical criteria for serrated polyposis (SP) ( 9 ) ( Table 1 ) .
Individuals who meet the clinical criteria for SP do appear to have an increased risk of CRC ( 10, 11 ) ; but, it is not yet clear if there is truly a familial form of SP and if so what the magnitude of risk for SP or cancer is in relatives of patients with SP. Jass et al. ( 2 ) were among the fi rst to suggest the existence of a familial form of SP when they described families with multiple cancers in whom serrated colonic polyps were prominent. Th ere are even putative genetic loci for SP; for example, Rashid et al. ( 12 ) reported familial aggregation of SP and found it to be associated with loss of heterozygosity at chromosome 1p and more recently Roberts et al. ( 13 ) reported linkage of familial serrated polyp syndrome (now referred to as Jass syndrome) to chromosome 2q32.2-q33.3. Th ese etiologic clues may well be the fi rst step towards a significant triumph in the genetic understanding of SP particularly when considering the contribution of similar linkage analyses in defi ning the cause of other hereditary CRC syndromes such as familial adenomatous polyposis and Lynch syndrome ( 14 ) . Importantly, no specifi c gene responsible for SP has yet been identifi ed. Th e lack of a genetic basis for SP is one of the major limitations in our understanding of this syndrome.
In this issue of American Journal of Gastroenterology , Win et al. ( 15 ) provide important new information in our expanding understanding of SP. Th ese authors gathered clinical information, through genetics clinics in Australia, New Zealand, and North America, on 100 individuals who met the WHO criteria # 1 or # 3 for SP ( Table 1 ) and on over 1,600 of their fi rst-and second-degree relatives. Th ey confi rmed that individuals with SP demonstrated several of the classic characteristics of a familial CRC syndrome including a high prevalence of CRC (31 % ) with synchronous CRCs in 10 % of these, a predilection for proximal location of CRCs (55 % ) and a younger than average age of onset of CRC (48 years). Importantly, they found that the fi rst-degree relatives of SP patients were at signifi cantly higher risk of CRC and pancreatic cancer than the extracolonic cancers (54 % ) among family members of patients with SP. Phenotype analysis, however, identifi ed three diff erent but overlapping phenotypes among their SP group: a group with relatively few large, right-sided polyps ( n = 55), a group with many small left -sided polyps ( n = 18), and a combination of both leftand right-sided polyps ( n = 42). Th ey noted that " those with the right-sided pattern had more sessile serrated polyps and had a younger age of CRC development. " Rosty et al. ( 11 ) agreed that SP likely represents a group of diseases rather than a single entity. Such phenotypic heterogeneity will complicate any attempts to discern the genetic basis of SP on clinical grounds alone and reinforces the need to vigorously pursue studies to fi nd the genetic basis of SP.
Like almost all early studies of rare conditions, the report by Win et al. ( 15 ) is limited by the need to obtain retrospective data from multiple centers that have diff erent patterns of referral, different clinical protocols, and variable degrees of completeness of data on probands and family members. In our opinion, the most notable shortcoming of this particular study is the lack of reporting the presence or absence of histologic confi rmation of cancer. Th is is particularly problematic since the fi nding that relatives of SP patients are at signifi cantly increased risks of colorectal and pancreatic cancer is the central fi nding, suggesting that SP is a familial cancer syndrome. Although lack of histologic confi rmation is a limitation for both colorectal and pancreatic cancer, it is critical that appropriate emphasis be given to the severe limitations in the diagnosis of pancreatic cancer in the absence of histologic verifi cation. One must be cognizant of the fact that adenocarcinomas of the pancreas may diff er from both an etiologic and genetic component from non-adenocarcinoma histologic types, such as neuroendocrine types, of pancreatic cancer. Win et al. ( 15 ) have given appropriate focus to the pancreatic cancer association in their familial cancer clusters; we believe that further attention to obtain more extended pedigrees, particularly those with pancreatic cancer and, indeed, embracing cancer of all anatomic sites inclusive of serrated adenomas through four or more generations whenever possible will be required to further defi ne the clinical spectrum of SP.
Other examples of limitations of this type of retrospective study design are that the authors were only able to interview family members of probands identifi ed by the Australian genetics clinics and only a portion of those. Similarly, important clinical data such as number of polyps and / or age at diagnosis of SP or CRC were not available for some probands and family members. Finally, even with an international eff ort, such as that of Win et al. ( 15 ) , only a small number of individuals with a rare condition can be gathered for this type of study. Taken together, these limitations highlight the importance of organizing prospective eff orts to study patients with SP and their families. Such eff orts could not only clarify the clinical features of SP, but also would provide the clinical platform for studies of the genetic cause(s) of this syndrome.
We believe that SP will ultimately be proven to have a hereditary basis and that it will take its place alongside the adenomatous and hamartomatous polyposis syndromes as one of the hereditary polyposis syndromes. Proof, however, will only come with the general population (standardized incidence rates of 5.16, 95 % CI 1.75 -2.93 and 3.64, 95 % CI 1.70 -9.21, respectively), but there was no detectable increase in risk of other cancers. Th ese data strongly support the concept that SP has an inherited component and highlights the importance of recognizing SP clinically and instituting proper screening / treatment for patients and their relatives, issues which are not as easy as they may seem.
Th ere are several clinical obstacles that currently complicate the recognition of SP including the continuing use of confusing terminology, challenges in the morphological recognition of and distinction between the types of serrated polyps and the recognition that serrated polyps, particularly those in the right colon, may be more diffi cult to detect, demarcate, and completely remove than conventional adenomas ( 9 ) . Substantial progress is being made, however, to overcome these obstacles. Th e increasing usage of the standard histologic classifi cation of serrated polyps proposed by the WHO ( 9,16 ) will help standardize the histologic reporting. Large-scale clinical investigations have improved the understanding of the clinical and endoscopic features of these lesions. Finally, reports that advanced imaging techniques such as narrow band imaging or chromoendoscopy can help identify and demarcate lesions may help endoscopists improve their ability to detect and completely remove these lesions ( 17, 18 ) . Although substantial variability in the detection rates of serrated polyps among endoscopists has been reported ( 19, 20 ) , Hetzel et al. ( 19 ) reported that the rates increased from 2006 to 2008, indicating that recognition of these lesions can be improved.
In the absence of a defi ning gene, clinical genetic studies are inherently diffi cult. Historically, multiple uncontrollable confounders such as incomplete penetrance, small family size, genetic heterogeneity involving phenotypic variants, and limited genealogic certitude have obfuscated the clinical understanding of the population genetics of CRC. When these confounders are coupled with the need to use less than an ideal study design, it limits the strength of the conclusions. Th e paper by Win et al. ( 15 ) illustrates several of the limitations inherent in attempts to defi ne a genetic syndrome on the basis of largely retrospective clinical data. In the absence of the ability to defi ne SP by genetic testing, the syndrome is described on the basis of clinical criteria ( (1) > 5 Serrated polyps proximal to the sigmoid colon with ≥ of these being > 10 mm; or (2) Any number of serrated polyps proximal to the sigmoid colon in an individual who has a fi rst-degree relative with serrated polyposis; or (3) > 20 Serrated polyps of any size, but distributed throughout the colon.
WHO, World Health Organization.
